

Michael Houghton

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8982326/michael-houghton-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

19,706
citations

70
h-index

139
g-index

190
ext. papers

21,043
ext. citations

9.9
avg, IF

5.94
L-index

#	Paper	IF	Citations
179	Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19. <i>BMC Pharmacology & Toxicology</i> , 2021 , 22, 61	2.6	2
178	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021 , 73, 1105-1116	11.2	2
177	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021 , 39, 5769-5779	4.1	4
176	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. <i>Cell Chemical Biology</i> , 2020 , 27, 780-792.e5	8.2	9
175	Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. <i>PLoS Pathogens</i> , 2020 , 16, e1008515	7.6	22
174	A structure-based computational workflow to predict liability and binding modes of small molecules to hERG. <i>Scientific Reports</i> , 2020 , 10, 16262	4.9	6
173	Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs. <i>Canadian Liver Journal</i> , 2020 , 3, 276-285	0.3	0
172	Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2020 , 60, 6566-6578	6.1	1
171	Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. <i>Scientific Reports</i> , 2019 , 9, 12392	4.9	57
170	Hepatitis C Virus: 30 Years after Its Discovery. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	7
169	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. <i>Journal of Hepatology</i> , 2019 , 70, 1082-1092	13.4	12
168	The Discovery of the Hepatitis C Virus. <i>Topics in Medicinal Chemistry</i> , 2019 , 19-27	0.4	
167	A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
166	Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. <i>Vaccines</i> , 2019 , 7,	5.3	13
165	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019 , 70, 593-602	13.4	11
164	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. <i>Virus Research</i> , 2018 , 248, 53-62	6.4	95
163	Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. <i>Journal of Virology</i> , 2018 , 92,	6.6	21

162 Hepatitis C Vaccines **2018**, 375-385.e5

161 Progress toward approval of an HCV vaccine. *Canadian Liver Journal*, **2018**, 1, 130-138 0.3 0

160 Progress toward approval of an HCV vaccine. *Canadian Liver Journal*, **2018**, 1-9 0.3

159 A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase. *Journal of Biological Chemistry*, **2018**, 293, 9696-9705 5.4 6

158 A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. *Journal of Immunological Methods*, **2017**, 445, 15-22 2.5 2

157 Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus. *Journal of Virology*, **2017**, 91, 6.6 24

156 Glycogen synthase kinase 3 inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism. *Scientific Reports*, **2017**, 7, 2495 4.9 22

155 Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. *Journal of Virology*, **2017**, 91, 6.6 25

154 Modeling the human Na1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade. *Drug Design, Development and Therapy*, **2017**, 11, 2301-2324 4.4 17

153 Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8 T Cell Responses to Chronic Viral Infections and Cancer. *Frontiers in Immunology*, **2017**, 8, 1215 8.4 55

152 Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets. *ACS Infectious Diseases*, **2016**, 2, 749-762 5.5 24

151 Towards the Control of Hepatitis C **2016**, 3-14

150 An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions. *Journal of Visualized Experiments*, **2016**, 1.6 14

149 Fabrication of flexible self-standing all-cellulose nanofibrous composite membranes for virus removal. *Carbohydrate Polymers*, **2016**, 143, 9-17 10.3 30

148 Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. *Cytokine*, **2016**, 78, 27-36 4 30

147 Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. *Liver Transplantation*, **2016**, 22, 324-32 4.5 12

146 A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. *ACS Infectious Diseases*, **2016**, 2, 872-881 5.5 9

145 Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. *Journal of Infectious Diseases*, **2015**, 212, 137-46 7 16

144	A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. <i>Journal of Chemical Information and Modeling</i> , 2015 , 55, 362-73 ^{6.1}	32
143	Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. <i>Drug Discovery Today</i> , 2015 , 20, 548-61	8.8 20
142	A human ether- γ -go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. <i>Toxicology Letters</i> , 2014 , 230, 382-92	4.4 37
141	Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 204-14	3.5 32
140	The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. <i>Emerging Microbes and Infections</i> , 2014 , 3, e51	18.9 109
139	Hepatitis C: the next 25years. <i>Antiviral Research</i> , 2014 , 110, 77-8	10.8 8
138	Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. <i>Journal of Virology</i> , 2014 , 88, 14278-88	6.6 53
137	Rational Drug Design. <i>International Journal of Computational Models and Algorithms in Medicine</i> , 2014 , 4, 59-85	3
136	IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. <i>PLoS Pathogens</i> , 2014 , 10, e1004556	7.6 72
135	Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2014 , 210, 717-27	7 59
134	HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α and Ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 458-65	3.4 15
133	Vaccine adjuvants--understanding molecular mechanisms to improve vaccines. <i>Swiss Medical Weekly</i> , 2014 , 144, w13940	3.1 20
132	Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design. <i>Journal of Chemical Information and Modeling</i> , 2013 , 53, 3031-43	6.1 21
131	Progress towards a hepatitis C virus vaccine. <i>Emerging Microbes and Infections</i> , 2013 , 2, e79	18.9 35
130	Hepatitis C vaccines 2013 , 1074-1084	
129	Structure and Molecular Virology 2013 , 219-245	
128	Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. <i>Journal of Hepatology</i> , 2013 , 59, 336-43	13.4 24
127	A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. <i>PLoS ONE</i> , 2013 , 8, e59776 ^{3.7}	112

126	A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. <i>Molecular Pharmaceutics</i> , 2013 , 10, 4572-89	5.6	9
125	Three isn't the magic number. <i>Nature Medicine</i> , 2013 , 19, 807	50.5	1
124	Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. <i>Hepatology</i> , 2013 , 58, 1907-17	11.2	49
123	Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. <i>PLoS ONE</i> , 2013 , 8, e68308	3.7	27
122	Minimum data elements for research reports on CFS. <i>Brain, Behavior, and Immunity</i> , 2012 , 26, 401-6	16.6	20
121	Chimp virus makes a savvy vaccine vector. <i>Science Translational Medicine</i> , 2012 , 4, 115fs1	17.5	1
120	Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. <i>Immunological Reviews</i> , 2011 , 239, 99-108	11.3	112
119	Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1186-90	7	79
118	Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. <i>Journal of Infectious Diseases</i> , 2011 , 204, 811-3	7	43
117	No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. <i>PLoS ONE</i> , 2011 , 6, e27870	3.7	12
116	Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. <i>Journal of Infectious Diseases</i> , 2010 , 202, 862-6	7	79
115	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. <i>Vaccine</i> , 2010 , 28, 6367-73	4.1	155
114	Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. <i>Hum Vaccin</i> , 2009 , 5, 151-7		80
113	Discovery of the hepatitis C virus. <i>Liver International</i> , 2009 , 29 Suppl 1, 82-8	7.9	61
112	The long and winding road leading to the identification of the hepatitis C virus. <i>Journal of Hepatology</i> , 2009 , 51, 939-48	13.4	94
111	Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. <i>Journal of Virology</i> , 2008 , 82, 7492-503	6.6	46
110	Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. <i>Journal of Virology</i> , 2008 , 82, 5109-14	6.6	36
109	Effect of IL-12 on T-cell immune responses in patients with chronic HCV infection. <i>Apmis</i> , 2008 , 108, 531-538	3.4	3

108	Hepatitis C virus vaccines 2008 , 1187-1199		1
107	The way forward in HCV treatment--finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 991-1000	10.4	243
106	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. <i>Vaccine</i> , 2007 , 25, 7773-84	4.1	70
105	Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. <i>Journal of General Virology</i> , 2006 , 87, 2253-2262	4.9	40
104	Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. <i>Journal of Virology</i> , 2006 , 80, 12131-40	6.6	21
103	Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). <i>Journal of Hepatology</i> , 2005 , 42, 499-504	13.4	25
102	Prospects for a vaccine against the hepatitis C virus. <i>Nature</i> , 2005 , 436, 961-6	50.4	270
101	Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. <i>Virology</i> , 2005 , 332, 438-53	3.6	65
100	Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 18544-9	11.5	223
99	Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. <i>Journal of Virology</i> , 2004 , 78, 10328-35	6.6	94
98	Association of hepatitis C virus envelope proteins with exosomes. <i>European Journal of Immunology</i> , 2004 , 34, 2834-42	6.1	155
97	Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. <i>Vaccine</i> , 2004 , 22, 457-66	4.1	12
96	Cationic microparticles are a potent delivery system for a HCV DNA vaccine. <i>Vaccine</i> , 2004 , 23, 672-80	4.1	64
95	Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1645-55	16.6	512
94	Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. <i>Journal of Virology</i> , 2003 , 77, 810-2	6.6	118
93	Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. <i>Virology</i> , 2002 , 304, 187-96	3.6	42
92	CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfecting with HCV and human immunodeficiency virus who responded to anti-HCV treatment. <i>Journal of Infectious Diseases</i> , 2002 , 186, 302-11	7	11
91	Characterization of liver T-cell receptor gamma delta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. <i>Hepatology</i> , 2001 , 33, 1312-20	11.2	60

90	Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. <i>Hepatology</i> , 2001 , 33, 1479-87	11.2	176
89	Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. <i>Journal of Virology</i> , 2001 , 75, 7142-8	6.6	78
88	Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. <i>Journal of Immunology</i> , 2001 , 166, 3589-98	5.3	94
87	Folding of hepatitis C virus E1 glycoprotein in a cell-free system. <i>Journal of Virology</i> , 2001 , 75, 11205-17	6.6	40
86	Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. <i>Journal of Infectious Diseases</i> , 2001 , 183, 1187-94	7	33
85	The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. <i>Immunity</i> , 2001 , 15, 883-95	32.3	336
84	7 Humoral response to hepatitis C virus. <i>Biomedical Research Reports</i> , 2000 , 2, 125-145		3
83	Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. <i>Nature Medicine</i> , 2000 , 6, 1082-6	50.5	76
82	Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA. <i>Hepatology</i> , 2000 , 31, 1327-33	11.2	6
81	Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. <i>Hepatology</i> , 2000 , 32, 597-603	11.2	91
80	Structure-function analysis of hepatitis C virus envelope-CD81 binding. <i>Journal of Virology</i> , 2000 , 74, 4824-30	6.6	172
79	Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. <i>Journal of Virology</i> , 2000 , 74, 6885-92	6.6	65
78	Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. <i>Vaccine</i> , 2000 , 18, 1962-8	4.1	13
77	Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. <i>Journal of General Virology</i> , 2000 , 81, 2451-2459	4.9	67
76	Analysis of a successful immune response against hepatitis C virus. <i>Immunity</i> , 1999 , 10, 439-49	32.3	689
75	Comparison of secretion of a hepatitis C virus glycoprotein in <i>Saccharomyces cerevisiae</i> and <i>Kluyveromyces lactis</i> . <i>Research in Microbiology</i> , 1999 , 150, 179-87	4	12
74	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999 , 31, 990-6	13.4	15
73	Perspectives for a vaccine against hepatitis C virus. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 259-63	13.4	34

72	Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. <i>Gastroenterology</i> , 1999 , 117, 926-32	13.3	133
71	Prospects for a hepatitis C virus vaccine. <i>Clinics in Liver Disease</i> , 1999 , 3, 901-15	4.6	7
70	Activation of the grp78 and grp94 promoters by hepatitis C virus E2 envelope protein. <i>Journal of Virology</i> , 1999 , 73, 3718-22	6.6	99
69	High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. <i>Hepatology</i> , 1998 , 28, 1117-20	11.2	126
68	Binding of hepatitis C virus to CD81. <i>Science</i> , 1998 , 282, 938-41	33.3	1547
67	Hepatitis C virus heteroduplex tracking assay for genotype determination reveals diverging genotype 2 isolates in Italian hemodialysis patients. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 227-33	9.7	17
66	Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. <i>Journal of Infectious Diseases</i> , 1997 , 176, 859-66	7	126
65	Hepatitis C virus core and E2 protein expression in transgenic mice. <i>Hepatology</i> , 1997 , 25, 719-27	11.2	120
64	Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. <i>Journal of Virology</i> , 1997 , 71, 2241-51	6.6	83
63	Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. <i>Journal of Virology</i> , 1997 , 71, 6011-9	6.6	240
62	A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 1759-63	11.5	296
61	Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. <i>Journal of Virology</i> , 1996 , 70, 7092-102	6.6	215
60	Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. <i>Journal of Clinical Investigation</i> , 1996 , 98, 706-14	15.9	512
59	Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. <i>Journal of Clinical Investigation</i> , 1996 , 98, 1432-40	15.9	233
58	Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 2755-9	11.5	298
57	Induction in vitro of a primary human antiviral cytotoxic T cell response. <i>European Journal of Immunology</i> , 1995 , 25, 627-30	6.1	48
56	Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. <i>Journal of Virology</i> , 1995 , 69, 32-8	6.6	83
55	Immune responses to plasmid DNA encoding the hepatitis C virus core protein. <i>Journal of Virology</i> , 1995 , 69, 5859-63	6.6	108

54	Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. <i>Journal of Clinical Investigation</i> , 1995 , 95, 521-30	15.9	259
53	HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. <i>Journal of Clinical Investigation</i> , 1995 , 96, 2311-21	15.9	231
52	Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. <i>Liver</i> , 1994 , 14, 65-70		15
51	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994 , 19, 1321-1324	11.2	854
50	Complex processing and protein:protein interactions in the E2:NS2 region of HCV. <i>Virology</i> , 1994 , 204, 114-22	3.6	118
49	Hepatitis C virus: structure, protein products and processing of the polyprotein precursor. <i>Current Studies in Hematology and Blood Transfusion</i> , 1994 , 61, 1-11		17
48	Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. <i>Journal of Virology</i> , 1994 , 68, 4420-6	6.6	35
47	Hepatitis C Virus-specific Cytotoxic T Lymphocytes Restricted by HLA-A2 are Present in the Peripheral Blood of Patients with Chronic Hepatitis C 1994 , 190-194		
46	HCV-positive, HIV-1-negative Mothers Transmit HCV 1994 , 463-467		
45	The Hepatitis C Virus: Genetic Organization, Persistence, and Vaccine Strategies 1994 , 33-37		3
44	The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 192, 399-406	3.4	173
43	Use of recombinant HCV antigen in the serodiagnosis of hepatitis C virus infection: Significant improvement in HCV antibody detection as compared with the first generation HCV C100-3 ELISA and the synthetic peptide EIA tests. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993 , 8, S33-S39	4	5
42	Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. <i>Gut</i> , 1993 , 34, S124-5	19.2	9
41	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. <i>Journal of Experimental Medicine</i> , 1993 , 178, 17-25	16.6	221
40	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. <i>Gastroenterology</i> , 1993 , 104, 580-7	13.3	297
39	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. <i>Hepatology</i> , 1993 , 18, 497-502	11.2	118
38	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- α b. <i>Hepatology</i> , 1993 , 18, 1300-1305	11.2	144
37	Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. <i>Journal of Virology</i> , 1993 , 67, 6753-61	6.6	154

36	A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. <i>Journal of Virology</i> , 1993 , 67, 4365-8	6.6	100
35	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients 1993 , 18, 497		10
34	Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach. <i>Seminars in Liver Disease</i> , 1992 , 12, 279-88	7.3	28
33	Group specific sequences and conserved secondary structures at the 3'Send of HCV genome and its implication for viral replication. <i>Nucleic Acids Research</i> , 1992 , 20, 3520	20.1	28
32	Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. <i>Gastroenterology</i> , 1992 , 103, 622-9	13.3	143
31	5'Send-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5'Suntranslated region. <i>Virology</i> , 1992 , 191, 889-99	3.6	65
30	Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. <i>Virology</i> , 1992 , 188, 819-30	3.6	109
29	Early antihepatitis C virus response with second-generation C200/C22 ELISA. <i>Vox Sanguinis</i> , 1992 , 62, 208-12	3.1	53
28	Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. <i>Vox Sanguinis</i> , 1992 , 62, 213-7	3.1	47
27	Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1992 , 15, 187-90	11.2	77
26	Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. <i>Journal of Clinical Microbiology</i> , 1992 , 30, 3220-4	9.7	101
25	Application of Polymerase Chain Reaction to Hepatitis C Virus Research and Diagnostics. <i>Frontiers of Virology</i> , 1992 , 86-100		1
24	Antibody to the hepatitis C virus in acute hepatitis and chronic liver diseases in Japan. <i>Liver</i> , 1991 , 11, 65-70		40
23	Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5'Suntranslated region and poly(A) tails at the 3'Send. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 1711-5	11.5	329
22	Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. <i>Annals of Internal Medicine</i> , 1991 , 115, 882-4	8	34
21	Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis. <i>Gastroenterology</i> , 1991 , 101, 1117-9	13.3	23
20	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991 , 180, 842-8	3.6	537
19	Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991 , 36, 1130-3	4	27

18	Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. <i>Hepatology</i> , 1991 , 14, 381-388	11.2	734
17	A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. <i>Cancer</i> , 1991 , 67, 429-33	6.4	270
16	Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. <i>Lancet, The</i> , 1991 , 337, 317-9	40	457
15	Vertical transmission of hepatitis C virus. <i>Lancet, The</i> , 1991 , 338, 17-8	40	238
14	Rabbit-derived anti-HD antibodies for HDAg immunoblotting. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S130-3	13.4	1
13	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S6-14	13.4	42
12	Hepatitis C virus replication in autoimmune chronic hepatitis. <i>Journal of Hepatology</i> , 1991 , 13, 364-7	13.4	55
11	Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. <i>Journal of Clinical Microbiology</i> , 1991 , 29, 2528-34	9.7	98
10	Prevalence of anti-HCV antibody in blood donors in the Tokyo area. <i>Vox Sanguinis</i> , 1990 , 59, 86-8	3.1	59
9	Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. <i>Nucleic Acids Research</i> , 1990 , 18, 4626	20.1	84
8	Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. <i>Gene</i> , 1990 , 91, 287-91	3.8	75
7	Hepatitis C antibody and chronic liver disease in haemophilia. <i>Lancet, The</i> , 1990 , 335, 1117-9	40	204
6	HCV testing in low-risk population. <i>Lancet, The</i> , 1990 , 336, 695	40	63
5	Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. <i>Lancet, The</i> , 1990 , 335, 873-4	40	214
4	A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. <i>Nucleic Acids Research</i> , 1989 , 17, 10367-72	20.1	145
3	Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. <i>New England Journal of Medicine</i> , 1989 , 321, 1494-500	59.2	1460
2	Structure, sequence and expression of the hepatitis delta (delta) viral genome. <i>Nature</i> , 1986 , 323, 508-14	30.4	615
1	Structure and Molecular Virology 379-406		0

